| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 13, 2002
From the Department of Surgery (B.P.-S., M.N.M.) and Renal Unit (R.H., G.T.H.), Medical Services, Massachusetts General Hospital, Harvard Medical School, Boston, Mass. * To whom correspondence should be addressed. E-mail: haupert.garner{at}mgh.harvard.edu.
AbstractConservation of the binding site on mammalian Na+,K+-ATPase for cardiac glycosides and the importance of the Na+ pump in mammalian cellular physiology has stimulated the search for a mammalian analog of these plant compounds. One candidate, isolated from brain and blood, appears to be ouabain itself or a closely related isomer, the ouabain-like compound. Little is known about the circulating form. Because human steroid hormones circulate with carrier proteins, we produced a ouabain-specific monoclonal antibody (mAb 1-10) and used it to probe normal human plasma for ouabain-protein carrier complex. Ouabain-like biological activity was isolated in association with protein bands of 80, 50, and 25 kDa. These proteins appear to be human immunoglobulins or immunoglobulin-like because they are recognized by anti-human immunoglobulin antibodies, but not by anti-mouse immunoglobulin antibodies. The protein-containing fractions inhibit the binding of mAb 1-10 to immobilized ouabain, and with further purification on protein A, the immunoglobulin-like protein binds radioactive ouabain with an IC50 of 200 to 600 nmol/L, but binds digoxin with 100-fold less affinity, suggesting specificity for ouabain or its isomer. Active protein fractions after purification on C18 inhibit Na+ pump activity in human erythrocytes (IC50
Revised on June 3, 2002
Ouabain-Binding Protein(s) From Human Plasma
Behnaz Parhami-Seren;
4 nmol/L, ouabain equivalents), and this chromatography appears to dissociate the ouabain-like compound from the immunoglobulin protein(s). These immunoglobulin-like molecules may represent a subset of immunoglobulins (
0.5% of total protein A immunoglobulin) that function as a reservoir and delivery system for ouabain-like compounds in the modulation of human Na+,K+-ATPase in vivo.
This article has been cited by other articles:
![]() |
A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dostanic-Larson, J. N. Lorenz, J. W. Van Huysse, J. C. Neumann, A. E. Moseley, and J. B Lingrel Physiological role of the {alpha}1- and {alpha}2-isoforms of the Na+-K+-ATPase and biological significance of their cardiac glycoside binding site Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R524 - R528. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dostanic-Larson, J. W. Van Huysse, J. N. Lorenz, and J. B Lingrel From The Cover: The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation PNAS, November 1, 2005; 102(44): 15845 - 15850. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bauer, J. Muller-Ehmsen, U. Kramer, N. Hambarchian, C. Zobel, R. H.G. Schwinger, H. Neu, U. Kirch, E.-G. Grunbaum, and W. Schoner Ouabain-Like Compound Changes Rapidly on Physical Exercise in Humans and Dogs: Effects of {beta}-Blockade and Angiotensin-Converting Enzyme Inhibition Hypertension, May 1, 2005; 45(5): 1024 - 1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M.A.M. Qazzaz, Z. Cao, D. D. Bolanowski, B. J. Clark, and R. Valdes Jr De Novo Biosynthesis and Radiolabeling of Mammalian Digitalis-Like Factors Clin. Chem., March 1, 2004; 50(3): 612 - 620. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |